BrightSpring Health Sees 36% Specialty Revenue Jump, $71 Price Target
BTSG•Goldman Sachs initiated coverage on BrightSpring Health with a Buy rating and set a $71.00 price target, implying 23.7% upside from recent trading levels. The company’s specialty and infusion revenues jumped 36% to $2.64 billion, but it forecasts a $600 million 2026 revenue headwind from drug reimbursement changes.
1. Analyst Coverage and Price Target
Goldman Sachs initiated coverage on BrightSpring Health with a Buy rating and set a $71.00 price target, implying roughly 23.7% upside from recent trading levels.
2. Robust Revenue Growth
The company's specialty and infusion revenues rose 36% to $2.64 billion in the latest period, contributing to a 56.2% year-to-date share rally driven by integration of Amedisys and LHC Group operations.
3. Projected 2026 Revenue Impact
BrightSpring forecasts a $600 million revenue headwind in 2026 due to drug reimbursement changes under the Inflation Reduction Act and a broader market shift toward generics.
4. Integration Challenges
The large-scale integrations of Amedisys and LHC Group present operational risks that could affect profitability and service delivery during consolidation.
